- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Patent holdings for IPC class C07K 16/30
Total number of patents in this class: 11459
10-year publication summary
869
|
1040
|
1084
|
1099
|
1135
|
1065
|
1080
|
1028
|
939
|
376
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Immatics Biotechnologies GmbH | 1151 |
410 |
Genentech, Inc. | 3927 |
201 |
Regeneron Pharmaceuticals, Inc. | 4201 |
149 |
F. Hoffmann-La Roche AG | 7908 |
144 |
Hoffmann-La Roche Inc. | 3352 |
144 |
The Regents of the University of California | 19780 |
143 |
Memorial Sloan-Kettering Cancer Center | 1901 |
131 |
The United States of America, as represented by the Secretary, Department of Health and Human Services | 2832 |
130 |
The Trustees of the University of Pennsylvania | 4289 |
115 |
Amgen Inc. | 4012 |
111 |
Chugai Seiyaku Kabushiki Kaisha | 1330 |
107 |
Janssen Biotech, Inc. | 1505 |
105 |
Amgen Research (Munich) GmbH | 252 |
93 |
Novartis AG | 10975 |
89 |
Immunomedics, Inc. | 267 |
89 |
SeaGen Inc | 578 |
87 |
The Board of Trustees of the Leland Stanford Junior University | 6322 |
86 |
Board of Regents, The University of Texas System | 5736 |
82 |
Dana-Farber Cancer Institute, Inc. | 2545 |
79 |
Daiichi Sankyo Company, Limited | 1848 |
76 |
Other owners | 8888 |